Applied Filters
English High Court upholds Sequenom patent for prenatal test
US-based gene sequencing company Sequenom was handed a win yesterday after a UK court ruled that The Doctors Laboratory and Ariosa Diagnostics, which is owned by Roche, had infringed its patent.
US patent reforms could re-establish gene patent eligibility, industry experts warn
A group of more than 100 medical, scientific, patient advocacy and women’s health organisations have opposed a recent proposal to amend section 101 of the US Patent Act.
Danish biotech company secures CRISPR licence
Danish research company Bioneer has secured a non-exclusive licence to CRISPR/Cas9 technology owned by French geneticist Emmanuelle Charpentier.
Sensorion in gene therapy collaboration with Institut Pasteur
Biopharmaceutical company Sensorion has entered into a research collaboration with French research body Institut Pasteur.
BGI takes Illumina to court over patent infringement in US
A subsidiary of China-based genome sequencing company BGI has filed a patent infringement suit against a US competitor.
University of California granted fifth CRISPR patent
The US Patent and Trademark Office has issued a new CRISPR/Cas9 patent to the University of California, the University of Vienna and microbiologist Emmanuelle Charpentier.
Google fund invests in CRISPR start-up
Alphabet-owned GV has invested in Verve Therapeutics, a cardiovascular company developing gene editing therapies aiming to permanently reduce the risk of coronary artery disease.
Charpentier granted new CRISPR/Cas9 patent
ERS Genomics has announced a new CRISPR/Cas9 US patent for use of the gene-editing technology in a single guide format.
US university treats cancer patients with CRISPR
The University of Pennsylvania has treated two cancer patients with CRISPR/Cas 9, a gene-editing technology that allows precise modifications to DNA.
Catalent to buy $1.2bn gene therapy company
Contract drug manufacturer Catalent has agreed to acquire Paragon Bioservices, a viral vector development and manufacturing partner for gene therapies, for $1.2 billion.
